Trade secrets vs patents is a choice between telling the public how your invention works in exchange for a fixed period of exclusivity, or keeping it quiet and hoping nobody else figures it out. Biotech companies rarely pick only one. They patent what a competitor could see or reverse-engineer from the product, and they keep secret the know-how that is hard to copy, such as process details, cell lines and data. This article covers US federal law, checked October 10, 2026.

The right answer for any specific invention depends on facts no article can know. The framework below is how practitioners think about it.

What each one actually gives you

Question Patent Trade secret
Is the invention made public? Yes, in detail, normally about 18 months after filing No
How long does protection last? A fixed term, after which competitors may copy Indefinitely, while secrecy holds
Can a rival lawfully copy it? Not while the patent is in force, even if they invent it independently Yes, by independent discovery or reverse engineering
Does it need a government filing? Yes, with examination No, but you must take reasonable steps to keep it secret
Main risk Eligibility, enablement and invalidity challenges One leak ends it

Patents are public by design. The Patent Act says applications are generally published 18 months after the earliest filing date, with an exception for applicants who certify they will not file abroad (35 U.S.C. 122). That makes a patent a trade: the public learns how to do it, and the owner gets a monopoly for a limited time.

What counts as a trade secret

Under the federal Defend Trade Secrets Act, information qualifies only if two things are true. The owner has taken “reasonable measures” to keep it secret, and it derives value from not being generally known or easily found out by lawful means (18 U.S.C. 1839).

The statute is also explicit about what is not wrongdoing. “Improper means” covers theft, bribery, misrepresentation and breach of a duty to keep a secret. It does not include reverse engineering or independent derivation. If a competitor buys your product and works out how it was made, that is generally lawful.

Secrecy is therefore not a legal shield, only a legal remedy when someone breaks a rule. Where misappropriation is proven, the available remedies include injunctions and damages, and the federal act can reach some overseas theft when acts in furtherance occur in the US, according to a Life Sciences IP Review article.

Why biotech is a special case

Two features of the field push companies toward secrecy more than they might in, say, mechanical engineering.

  1. Eligibility uncertainty. After the Supreme Court’s Mayo, Alice and Myriad decisions, some biological discoveries and diagnostic methods are hard to patent. The Life Sciences IP Review article names this uncertainty as a reason trade secrets have become more attractive. The federal trade secret definition has no such gate, so a diagnostic algorithm or a dataset can qualify when a patent claim might not.
  2. Know-how that travels poorly on paper. An IBA article on biotech collaborations notes that protocols, cell lines and manufacturing techniques often sit beside patents because the invention can be hard to reproduce without them.

The tougher enablement standard matters too. In Amgen v. Sanofi, decided May 18, 2023, a unanimous Supreme Court held Amgen’s broad antibody claims not enabled, because the patent described only 26 antibodies by sequence yet claimed a whole functional class. “The more one claims, the more one must enable,” the Court said (opinion text). The lesson for strategy: a patent that must teach everything it claims may force disclosure of more than a company wants to reveal.

A sorting checklist for common biotech assets

This is a rule-of-thumb map, not a prescription. Individual facts change the answer.

  • The composition of a drug candidate. Usually patent. It is visible in the product, regulators and competitors will analyze it, and secrecy is not realistic.
  • Methods of treatment and dosing. Usually patent, since the labeled use is public once a drug is marketed.
  • Manufacturing process details. Often secret. Process know-how, such as culture conditions and purification steps, may be hard to deduce from the finished product. The IP trade-off is that a rival who independently develops the same process is free to use it.
  • Cell lines and reagents. Often secret, sometimes alongside patents on what they produce.
  • Datasets, models and screening results. Often secret, partly because data may not be patent-eligible by itself.
  • Negative results and failed routes. Secret by default, with real strategic value.

The Life Sciences IP Review article lists real-world examples of secrecy in life sciences, among them extraction processes for a hormone drug from mares’ urine, sustained-release pellet technology and liposome formulations. I could not independently verify each example.

A worked example: one antibody program, three assets

Take an imagined company developing an antibody drug. This is a teaching sketch, not a real case.

  1. The antibody itself. Once it enters trials and reaches pharmacies, anyone can analyze it. The company files for a patent on the molecule and its use, accepting that the application will be published.
  2. The cell line and culture recipe. The product reveals little about how the cells were engineered or fed. The company keeps this as a trade secret, restricts access to a short list of staff, and requires contract manufacturers to sign confidentiality terms.
  3. The screening data. Hundreds of failed candidates tell competitors which routes not to try. Nobody would patent that, and the company guards it as a secret too.

Each asset sits where its weaknesses hurt least. The patent covers what cannot be hidden; the secret covers what cannot be seen. If the company later wanted broad antibody claims, the Amgen decision above would push it to disclose more than it might like, which is the tension to weigh up front.

The hybrid strategy most companies use

The IBA piece describes a hybrid approach: keep early-stage or hard-to-replicate innovations secret, and patent the elements competitors could reverse-engineer. It adds that when filing patents, applicants should identify background processes and formulations that can stay undisclosed.

That has a practical edge, and also a legal one. A patent specification still has to enable the claims. Burying the key detail to preserve a secret can leave the patent open to challenge. The more breadth a company claims, the more it has to teach. So the line between patent and secret is not drawn once; it is redrawn at every filing.

The prior-use safety net, and its limits

There is one more interaction. If you keep a manufacturing process secret and someone else later patents the same process, you are not necessarily out of luck. The Patent Act provides a defense for a person who, in good faith, commercially used the subject matter in the US at least one year before the other party’s effective filing date, and who proves it by clear and convincing evidence (35 U.S.C. 273).

The defense is narrow. It covers only the specific subject matter shown to have been used, with variations in quantity and non-infringing improvements, and it is not a general license. A university-owned invention generally cannot be attacked with it unless the work could have been funded without federal money. Companies relying on secrecy for processes still do well to document when each process went into commercial use.

Protecting a secret in practice

Because the legal test turns on “reasonable measures,” the practical work is administrative. The IBA article recommends confidentiality clauses that bind the counterparty and its employees, disclosure limited to what a deal strictly requires, clear separation between existing IP and what is created during a collaboration, and employment contracts with post-termination restrictions. It also warns that investors may find secrets harder to value than registered patents.

One leak through an employee, a partner or an accident cannot be undone by any later remedy. That is the central risk, and it is why valuable secrets are usually divided so that no single person knows everything.

Common questions

Can I keep something secret and patent it later?

Careful here. Once you commercially use or publicly disclose an invention, the clock on patent filing can start running under rules I did not review for this article. Ask a patent attorney before relying on this.

Does a trade secret stop a competitor from making the same product?

Only if they got your secret improperly. If they work it out themselves or reverse-engineer a product they lawfully bought, the law generally allows it.

Why not just patent everything?

Cost, timing, eligibility and the disclosure itself. A patent also ends. A company with a process that is hard to copy may prefer an open-ended secret.

Are cell and gene therapy companies different?

Morrison Foerster describes the patent versus trade secret choice as increasingly important and difficult for these developers, though I could read only an excerpt of that piece.

This is general information about US federal law, not legal advice.

Sources